ADVERTISEMENT RETURN TO ISSUEEditorialNEXTOral Bioperformance and 21st Century DissolutionGregory E. Amidon and Michael HawleyView Author Information College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109 Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340Cite this: Mol. Pharmaceutics 2010, 7, 5, 1361Publication Date (Web):September 8, 2010Publication History Received19 August 2010Published online8 September 2010Published inissue 4 October 2010https://pubs.acs.org/doi/10.1021/mp100275bhttps://doi.org/10.1021/mp100275beditorialACS PublicationsCopyright © 2010 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views1273Altmetric-Citations10LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstract
No takes yet. Share an insight, caveat, or question.
Amidon et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: